The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1

International Journal of Tryptophan Research

Volumn 6, Issue , 2013, Pages

  Flick, Hollie E ^a,b   LaLonde, Judith M ^c   Malachowski, William P ^c   Muller, Alexander J ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c BRYN MAWR COLLEGE   (United States)

Author keywords

beta lapachone; cancer; IDO; immunotherapy; indoleamine 2,3 dioxygenase; inhibitor; naphthoquinone; tryptophan

Indexed keywords

EID: 85128771179     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S12094     Document Type: Article

References (49)

1. Liu X., Newton R.C., Friedman S.M., Scherle P.A. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets. 2009; 9(8): 938–52.
2. Soliman H., Mediavilla-Varela M., Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J. 2010; 16(4): 354–9.
3. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov. 2002; 1(8): 609–20.
4. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991; 5(11): 2516–22.
5. Munn D.H., Zhou M., Attwood J.T. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998; 281: 1191–3.
6. Muller A.J., Sharma M.D., Chandler P.R. et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA. 2008; 105(44): 17073–8.
7. Smith C., Chang M.Y., Parker K.H. et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012; 2(8): 722–35.
8. Banerjee T., DuHadaway J.B., Gaspari P. et al. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene. 2008; 27(20): 2851–7.
9. Hou D.Y., Muller A.J., Sharma M.D. et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007; 67(2): 792–801.
10. Kumar S., Malachowski W.P., Duhadaway J.B. et al. Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008; 51(6): 1706–18.
11. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005; 11(3): 312–9.
12. Muller A.J., DuHadaway J.B., Jaller D., Curtis P., Metz R., Prendergast G.C. Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res. 2010; 70(5): 1845–53.
13. Muller A.J., Prendergast G.C. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res. 2005; 65(18): 8065–8.
14. Chen L., McGowan P., Ashe S. et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994; 179(2): 523–32.
15. Kruczynski A., Hill B.T. Classic in vivo cancer models: three examples of mouse models used in experimental therapeutics. Curr Protoc Pharmacol. 2002; Chapter 5: Unit5 24.
16. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999; 190(3): 355–66.
17. Gaspari P., Banerjee T., Malachowski W.P. et al. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2006; 49(2): 684–92.
18. Halgren T.A. MMFF VI. MMFF94 s option for energy minimization studies. J Comput Chem. 1999; 20: 720–9.
19. Halgren T.A. MMFF VII. Characterization of MMF94, MMF94 s, and other widely available force fields for conformational engergies and for intermolecular-interaction energies and geometries. J Comput Chem. 1999; 20: 740–74.
20. Sugimoto H., Oda S.I., Otsuki T., Hino T., Yoshida T., Shiro Y. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA. 2006; 103(8): 2611–6.
21. Word J.M., Lovell S.C., Richardson J.S., Richardson D.C. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol. 1999; 285(4): 1735–47.
22. Lovell S.C., Davis I.W., Arendall WB 3rd et al. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins. 2003; 50(3): 437–450.
23. Ponder J.W., Case D.A. Force fields for protein simulations. Adv Protein Chem. 2003; 66: 27–85.
24. Kirton S.B., Murray C.W., Verdonk M.L., Taylor R.D. Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins. Proteins. 2005; 58(4): 836–44.
25. Littlejohn T.K., Takikawa O., Skylas D., Jamie J.F., Walker M.J., Truscott R.J.W. Expression and purification of recombinant human indoleamine 2,3-dioxygenase. Prot Exp Purif. 2000; 19(1): 22–9.
26. Sono M., Cady S.G. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. Biochemistry. 1989; 28(13): 5392–9.
27. Skehan P., Storeng R., Scudiero D. et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82(13): 1107–12.
28. Yue E.W., Douty B., Wayland B. et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem. 2009; 52(23): 7364–7.
29. Pink J.J., Planchon S.M., Tagliarino C., Varnes M.E., Siegel D., Boothman D.A. NAD(P)H: Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem. 2000; 275(8): 5416–24.
30. Boothman D.A., Pardee A.B. Inhibition of radiation-induced neoplastic transformation by beta-lapachone. Proc Natl Acad Sci USA. 1989; 86(13): 4963–7.
31. Li C.J., Averboukh L., Pardee A.B. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem. 1993; 268(30): 22463–8.
32. Vanni A., Fiore M., De Salvia R. et al. DNA damage and cytotoxicity induced by beta-lapachone: relation to poly(ADP-ribose) polymerase inhibition. Mutat Res. 1998; 401(1-2): 55–63.
33. Villamil S.F., Podesta D., Molina Portela M.D., Stoppani A. Characterization of poly(ADP-ribose)polymerase from Crithidia fasciculata: enzyme inhibition by beta-lapachone. Mol Biochem Parasitol. 2001; 115(2): 249–56.
34. Tagliarino C., Pink J.J., Dubyak G.R., Nieminen A.L., Boothman D.A. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J Biol Chem. 2001; 276(22): 19150–9.
35. Molina Portela M.P., Stoppani A.O. Redox cycling of beta-lapachone and related o-naphthoquinones in the presence of dihydrolipoamide and oxygen. Biochem Pharmacol. 1996; 51(3): 275–83.
36. Manna S.K., Gad Y.P., Mukhopadhyay A., Aggarwal B.B. Suppression of tumor necrosis factor-activated nuclear transcription factor-kappaB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by beta-lapachone. Biochem Pharmacol. 1999; 57(7): 763–74.
37. Li Y., Li C.J., Yu D., Pardee A.B. Potent induction of apoptosis by beta-lapachone in human multiple myeloma cell lines and patient cells. Mol Med. 2000; 6(12): 1008–15.
38. Li Y.Z., Li C.J., Pinto A.V., Pardee A.B. Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells. Mol Med. 1999; 5(4): 232–9.
39. Marin A., Lopez de Cerain A., Hamilton E. et al. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer. 1997; 76(7): 923–9.
40. Malkinson A.M., Siegel D., Forrest G.L. et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res. 1992; 52(17): 4752–7.
41. Belinsky M., Jaiswal A.K. NAD(P)H: quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev. 1993; 12(2): 103–17.
42. Joseph P., Xie T., Xu Y., Jaiswal A.K. NAD(P)H: quinone oxidoreductase1 (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res. 1994; 6(10-11): 525–32.
43. Yu S.W., Wang H., Poitras M.F. et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science. 2002; 297(5579): 259–63.
44. Bey E.A., Bentle M.S., Reinicke K.E. et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci USA. 2007; 104(28): 11832–7.
45. Edinger A.L., Thompson C.B. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol. 2004; 16(6): 663–9.
46. Sun X., Li Y., Li W. et al. Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway. Cell Cycle. 2006; 5(17): 2029–35.
47. Braidy N., Guillemin G.J., Grant R. Effects of kynurenine pathway inhibition on NAD metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res. 2011; 4: 29–37.
48. Hayaishi O. My life with tryptophan—never a dull moment. Protein Sci. 1993; 2: 472–5.
49. Balachandran V.P., Cavnar M.J., Zeng S. et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011; 17(9): 1094–100.